NCT03266757View on ClinicalTrials.gov

Borderline Resectable or Resectable or Advanced Pancreatic Adenocarcinoma

CompletedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

February 11, 2016

Primary Completion Date

February 11, 2017

Study Completion Date

February 11, 2018

Conditions
Pancreatic Adenocarcinoma
All Listed Sponsors
lead

Hellenic Society of Medical Oncology

OTHER

NCT03266757 - Borderline Resectable or Resectable or Advanced Pancreatic Adenocarcinoma | Biotech Hunter | Biotech Hunter